Response to Bistrian BR. Parenteral Fish‐Oil Emulsions in Critically Ill COVID‐19 Emulsions

In this letter we discuss the proposition of Bristian BR (2020) to use the intravenous administration of fish‐oil emulsions in critically ill patients with Coronavirus Disease 2019 (COVID‐19). We consider that immune‐modulatory properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, ra...

Full description

Saved in:
Bibliographic Details
Published in:JPEN. Journal of parenteral and enteral nutrition 2020-09, Vol.44 (7), p.1169-1170
Main Authors: Torrinhas, Raquel S., Calder, Philip C., Waitzberg, Dan L.
Format: Article
Language:English
Subjects:
Animals
COVID-19
Critical Illness
Docosahexaenoic Acids
Eicosapentaenoic Acid
Emulsions
Fat Emulsions, Intravenous
Fish Oils
Humans
Letter to the Editor
Letters to the Editor
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this letter we discuss the proposition of Bristian BR (2020) to use the intravenous administration of fish‐oil emulsions in critically ill patients with Coronavirus Disease 2019 (COVID‐19). We consider that immune‐modulatory properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, rapidly provided in high amounts by fish‐oil emulsions, may be important to change the course of COVID‐19's death pathway. Prescriptions should be based on body weight (eg, 0.2‐g pure fish‐oil lipid emulsion/kg body weight/d) and also should consider combining the parenteral administration of fish‐oil emulsions with low oral aspirin intake to trigger resolvin synthesis from EPA and DHA.
ISSN:0148-6071
1941-2444
DOI:10.1002/jpen.1933